The Business Research Company’s report on the Malignant Pleural Effusion Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the malignant pleural effusion market in recent years?
The rising cases of lung cancer is expected to propel the growth of the malignant pleural effusion market going forward. Lung cancer is a disease characterized by the uncontrolled growth of abnormal cells in the lungs, which can form tumors and interfere with normal lung function. The rising cases of lung cancer are due to smoking and tobacco use, as prolonged exposure to harmful chemicals in cigarettes damages lung tissues, triggers genetic mutations, and promotes the uncontrolled growth of cancerous cells, significantly increasing the likelihood of developing the disease. Malignant pleural effusion indicates advanced lung cancer progression by facilitating tumor spread within the pleural cavity, leading to worsened respiratory function and a poorer prognosis. For instance, in January 2023, according to the American Cancer Society Facts and Figures, a US-based professional organizations company, the estimated number of new lung and bronchus cancer cases was 236,740 in 2022 and 238,340 in 2023, while the estimated deaths were 130,180 in 2022 and 127,070 in 2023. Therefore, the rising cases of lung cancer is driving the growth of the malignant pleural effusion market.
Impact Of Improving Healthcare Infrastructure On The Market Due To Enhanced Diagnosis And Treatment Accessibility
The improving healthcare infrastructure is expected to propel the growth of the malignant pleural effusion market going forward. Healthcare infrastructure refers to the physical, technological, and organizational structures required for delivering healthcare services, including hospitals, clinics, medical equipment, IT systems, and workforce. Improving healthcare infrastructure is attributed to need for better disease management, all of which contribute to enhanced healthcare accessibility, efficiency, and quality of care. Improving healthcare infrastructure enhances the diagnosis, treatment, and management of malignant pleural effusion by enabling access to advanced medical technologies, better-equipped healthcare facilities, and specialized care, ultimately improving patient outcomes. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the United States increased by 0.591% from the previous year, rising from 6,093 to 6,129. Therefore, the improving healthcare infrastructure is driving the growth of the malignant pleural effusion market.
Access Your Free Sample of the Global Malignant Pleural Effusion Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp
What is the projected market size of the malignant pleural effusion industry, and how is it expected to grow?
The malignant pleural effusion market size has grown strongly in recent years. It will grow from $4.42 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the growing adoption of indwelling pleural catheters, increased focus on palliative allative care, increasing clinical trials, rising reimbursement, and rising metastatic malignancies.
The malignant pleural effusion market size is expected to see strong growth in the next few years. It will grow to $6.17 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing healthcare infrastructure, rising government support, increasing cancer survivors, rising demand for home-based care, growth in liquid biopsy. Major trends in the forecast period include the integration of artificial intelligence in imaging tools, advancements in targeted cancer therapies, advancements in pleurodesis, improvements in biomarkers, and expanding clinical trials for novel therapeutic agents.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22047&type=smp
Who are the key players driving competition in the malignant pleural effusion market?
Major companies operating in the malignant pleural effusion market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Medline Industries LP, Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., B Braun SE, Simcere Pharmaceutical Group Limited, pfm medical AG, Redax SpA, Wuhan YZY Biopharma Co. Ltd., Rocket Medical plc, Genelux Corporation, Gongwin Biopharm Holdings Co. Ltd., Ewimed GmbH
What key trends are expected to drive the malignant mesothelioma market during the forecast period?
Major companies operating in the malignant pleural effusion market are focusing on developing innovative therapies such as enzyme-targeting therapy to improve treatment outcomes by targeting specific enzymes involved in fluid accumulation. Enzyme-targeting therapy is a medical approach that involves designing drugs or treatments to specifically inhibit or modify the activity of enzymes associated with diseases. This therapy is commonly used in conditions such as cancer, metabolic disorders, and infectious diseases, where abnormal enzyme activity contributes to disease progression. For instance, in September 2022, RS Oncology, LLC, a US-based biotechnology company, Initiated the MITOPE clinical trial, a first-in-human Phase 1/2 trial conducted in the United Kingdom. This study is a Phase 1/2 trial assessing RSO-021, a novel PRX3 inhibitor designed to treat malignant pleural effusion and mesothelioma by targeting oxidative stress to eliminate cancer cells while preserving healthy tissue.
Which key geographies are driving the growth of the malignant pleural effusion market?
North America was the largest region in the malignant pleural effusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report
What are the key segments driving growth in the malignant pleural effusion market?
The malignant pleural effusion market covered in this report is segmented –
1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter
2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy
3) By End Users: Hospitals, Ambulatory Clinics, Other End Users
Subsegments:
1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis
3) By Thoracic Drainage And Pleurodesis:Chemical Pleurodesis, Mechanical Pleurodesis, Biological Pleurodesis
4) By Indwelling Pleural Catheter:Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22047
How is the malignant pleural effusion market defined?
Malignant pleural effusion (MPE) refers to the accumulation of fluid in the pleural space due to the presence of cancer cells, typically resulting from metastatic disease. This condition occurs when cancer spreads to the pleura, the thin membrane surrounding the lungs, leading to increased vascular permeability and impaired lymphatic drainage.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
